NCT02103699View on ClinicalTrials.gov

A Study to Examine Patient Characteristics, Health Care Management and Health Outcomes of Hepatitis C Virus (HCV) Patients Treated With Simeprevir

CompletedOBSERVATIONAL

Enrollment

315

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

November 30, 2015

Study Completion Date

January 31, 2016

Conditions

Hepatitis C Virus

Interventions

DRUG

No intervention

This is an observational study. Patients receiving simeprevir (single capsule of 150 mg once daily) as prescribed by the health care provider will be observed.

Trial Locations (32)

Unknown

Phoenix

Bakersfield

Beverly Hills

Los Angeles

Daytona Beach

DeLand

Miami

Tampa

West Palm Beach

Crestview Hills

Baltimore

Springfield

Newark

Vineland

Brooklyn

Flushing

New York

Durham

Fayetteville

Rocky Mount

Statesville

Winston-Salem

Cincinnati

Doylestown

Philadelphia

Nashville

Austin

Dallas

Fort Worth

Houston

Murray

Norfolk

All Listed Sponsors

lead

Janssen Scientific Affairs, LLC

INDUSTRY

NCT02103699 - A Study to Examine Patient Characteristics, Health Care Management and Health Outcomes of Hepatitis C Virus (HCV) Patients Treated With Simeprevir | Biotech Hunter | Biotech Hunter